RPubs will retire in June 2027. Your existing documents will stay accessible through December 31, 2031
and Connect Cloud is the recommended home for new publishing. Read the blog post
gravatar

avalex99

Andrey Alexeyenko

Recently Published

200 most DE and regressed
with day 4
Correlation with FGF
with day 4
678 monocytes vs. 160 DE genes (benign/malignant)
678 monocytes vs. 120 marker genes
70 EV and scRNA subsamples vs. 1657 fgs.clean.dbs pathways
70 EV and scRNA subsamples vs. 186 KEGG.2024 pathways
70 EV and scRNA subsamples vs. 658 KEGG.medicus pathways
70 EV and scRNA subsamples vs. 50 hallmarks
Bulk and pseudobulk; Markers
Bulk and pseudobulk; TFs
Bulk and pseudobulk; protein_coding
Selected_samples, protein coding: sample similarity
Selected_samples, TFs: sample similarity
Selected_samples, markers: sample similarity
All_samples, markers: sample similarity
All_samples, TFs: sample similarity
All_samples, protein coding: sample similarity
Bulk-seq sample similarity (All_samples, markers)
Bulk-seq sample similarity (All_samples, TFs)
Plot0
All LaManno2016 vs. Human_brain.Ramasamy2014
Single cell sums and bulk samples
Single cell sums vs. bulk samples (Kendall tau)
Single cell sums vs. bulk samples
Human_brain.Ramasamy2014 vs. random 1
Human_brain.Ramasamy2014 vs. Kirkby2017.Alpha_0.5.minL_0.01.Nfolds_3.1153972
2: Human_body_index.Roth vs. Kirkby2017
Human_body_index.Roth vs. Kirkby2017.Alpha_0.5.minL_0.01.Nfolds_3.1153972
test2
GLMnet signature vs. FANTOM5
Markers of high/low DA yield in human RNA atlas, v. 2, "bad" part
Markers of high/low DA yield in human RNA atlas, v. 2, "good" part
Markers of high/low DA yield in human RNA atlas; * Genes in the list by Kirkby et al., 2017
* Genes in the list by Kirkby et al., 2017
Kdm1a-Cd274.TISMO.invivo
test111
X: SLC29A1; Y: CDA; Z: DCK; Color: CYTARABINE (PREDICTED); Blue: MOST RESISTANT
X: SLC29A1; Y: CDA; Z: DCK; Color: CYTARABINE (OBSERVED); Blue: MOST RESISTANT
X: SLC29A1; Y: CDA; Z: SAMHD1; Color: CYTARABINE (PREDICTED); Blue: MOST RESISTANT
X: SLC29A1; Y: CDA; Z: SAMHD1; Color: CYTARABINE (OBSERVED); Blue: MOST RESISTANT
X: SLC29A1; Y: DCK; Z: SAMHD1; Color: CYTARABINE (PREDICTED); Blue: MOST RESISTANT
X: SLC29A1; Y: DCK; Z: SAMHD1; Color: CYTARABINE (OBSERVED); Blue: MOST RESISTANT
X: DCTD; Y: CDA; Z: DCK; Color: CYTARABINE (PREDICTED); Blue: MOST RESISTANT
X: DCTD; Y: CDA; Z: DCK; Color: CYTARABINE (OBSERVED); Blue: MOST RESISTANT
X: DCTD; Y: CDA; Z: SAMHD1; Color: CYTARABINE (PREDICTED); Blue: MOST RESISTANT
X: DCTD; Y: CDA; Z: SAMHD1; Color: CYTARABINE (OBSERVED); Blue: MOST RESISTANT
X: DCTD; Y: DCK; Z: SAMHD1; Color: CYTARABINE (PREDICTED); Blue: MOST RESISTANT
X: DCTD; Y: DCK; Z: SAMHD1; Color: CYTARABINE (OBSERVED); Blue: MOST RESISTANT
X: CDA; Y: DCK; Z: SAMHD1; Color: CYTARABINE (PREDICTED); Blue: MOST RESISTANT
X: CDA; Y: DCK; Z: SAMHD1; Color: CYTARABINE (OBSERVED); Blue: MOST RESISTANT
mRNAsamples_infoContent.NEA.heatmap
LSD1-PDL1-JAK2
test
SupplFigure.predicted_drivers_vs_hallmarks.PathReg.q05
artefactual genes were removed from each of the gene sets
SupplFigure.predicted_drivers_vs_hallmarks.MutSet&PathReg.q05
artefactual genes were removed from each of the gene sets
SupplFigure.predicted_drivers_vs_hallmarks.MutSet.q05
Artifactual genes removed from each of the cancer gene sets
SupplFigure.mutations_vs_hallmarks.MGS
SupplFigure.predicted_drivers_vs_hallmarks.MutSet.q05
SupplFigure.predicted_drivers_vs_hallmarks.PathReg.q05
SupplFigure.predicted_drivers_vs_hallmarks.MutSet&PathReg.q05
SupplFigure.predicted_drivers_vs_hallmarks.MutSet&PathReg.q05
SupplFigure.mutations_vs_hallmarks.MGS
SupplFigure.predicted_drivers_vs_hallmarks.PathReg.q05
SupplFigure.predicted_drivers_vs_hallmarks.MutSet.q05
SupplFigure.mutations_vs_hallmarks.MGS
HTML
regr test
SupplFigure.drivers_vs_hallmarks.driverProbs.05
SupplFigure.drivers_vs_hallmarks.driverProbs.01
SupplFigure.drivers_vs_hallmarks.MGS